Name: Compound 56
Price: 364.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. It competitively binds at the adenosine-triphosphate (ATP) site of EGFR. Compound 56 is capable of inhibiting the phosphorylation of EGF-dependent EGFR, suppressing the proliferation and clonogenicity of a wide panel of EGFR-overexpressing human cancer lines, and blocking EGF-mediated mitogenesis and oncogenic transformation in fibroblasts overexpressing EGFR. Besides inhibiting EGFR tyrosine kinase, It also inhibits the tyrosine kinase of human epidermal growth factor receptor 2 (HER2/neu) but with a less potency.
- Properties
  - Alternative Name
    
    N-(3-bromophenyl)-6,7-diethoxyquinazolin-4-amine
    
    CAS Number
    
    171745-13-4
    
    Molecular Formula
    
    C18H18BrN3O2
    
    Molecular Weight
    
    388.3
    
    Appearance
    
    A solid
    
    Purity
    
    97.00%
    
    Solubility
    
    insoluble in H2O; ≥16.95 mg/mL in DMSO; ≥47.6 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Duggan BM, Foley KP, et al."Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia." Sci Rep. 2017 May 8;7(1):1578. PMID:28484277

Compound 56

Compound 56

Background

We Also Recommend

DAPT (GSI-IX)

P 22077

PD153035 hydrochloride